Examples of these biomarkers that are in research for monitoring AD response to treatments are concentrations of NfL and GFAP, which could be also used as risk markers for conversion to AD dementia.27, 28Although they are not specific to AD, they reflect the severity of degeneration, as explained above. This evidence concerns the gene NEFL and Alzheimer disease.